Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist

Basit Öğe Kaydı
dc.authoridUlugol, Ahmet/0000-0003-4643-1124
dc.authoridGunduz, Ozgur/0000-0002-2470-3021
dc.authoridOZTURK, GOZDE/0000-0003-0196-2968
dc.authorwosidGÜNDÜZ, Özgür/AAH-8717-2019
dc.authorwosidUlugol, Ahmet/V-9665-2019
dc.authorwosidGunduz, Ozgur/A-2351-2016
dc.contributor.authorBilir, K. A.
dc.contributor.authorAnli, G.
dc.contributor.authorOzkan, E.
dc.contributor.authorGunduz, O.
dc.contributor.authorUlugol, A.
dc.date.accessioned2024-06-12T11:18:47Z
dc.date.available2024-06-12T11:18:47Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground. Cannabinoids have been used for their analgesic and euphoric effects for millennia, but recently the antipruritic effects of cannabis have been discovered. Considering the similarities between pain and itch sensations, we hypothesized that cannabinoid receptors may play a role in the antipruritic effects of cannabinoids. Aim. To analyse the role of the spinal cannabinoid receptors, CB1 and CB2, in the antipruritic effects of the cannabinoid agonist WIN 55,212-2. Methods. Male Balb/c mice weighing 20-30 g were used. Scratching behaviour in the mice was produced by injection of serotonin 5 g/50 L intradermally into the nape of the neck. Scratching of the site of injection by the hind paws was video-recorded for 30 min. After testing different doses of WIN 55,212-2 [1, 3 and 10 mg/kg intraperitoneally (IP)], the effects of the CB1 receptor antagonist, AM-251 [1 g/mouse administered intrathecally (IT)] and the CB2 receptor antagonist AM-630 (4 g/mouse IT) on the antipruritic effects of WIN 55,212-2 were studied using a rotarod apparatus. Results. WIN 55,212-2 (1, 3 or 10 mg/kg IP) dose-dependently decreased serotonin-induced scratches. The receptor antagonist CB1 partially reversed the effects of WIN 55,212-2 (P < 0.05); whereas CB2 had no statistically significant effect. WIN 55,212-2 impaired motor function only at the highest dose given (10 mg/kg, P < 0.05). Conclusions. Our findings support prior researches indicating that cannabinoids exert antipruritic effects. Moreover, our results show that the antipruritic effects of cannabinoids are partially mediated by spinal CB1 receptors.en_US
dc.description.sponsorshipTUBITAK [2209/A-1919B011500408]en_US
dc.description.sponsorshipThis work was supported by a grant from TUBITAK (2209/A-1919B011500408). The authors have no conflicts of interests to disclosure. We thank K. Duvan-Aydemir for technical assistance with the behavioural testing.en_US
dc.identifier.doi10.1111/ced.13398
dc.identifier.endpage558en_US
dc.identifier.issn0307-6938
dc.identifier.issn1365-2230
dc.identifier.issue5en_US
dc.identifier.pmid29424035en_US
dc.identifier.scopus2-s2.0-85041736184en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage553en_US
dc.identifier.urihttps://doi.org/10.1111/ced.13398
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24964
dc.identifier.volume43en_US
dc.identifier.wosWOS:000436106200007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofClinical And Experimental Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndocannabinoid Modulationen_US
dc.subjectScratching Behavioren_US
dc.subjectTherapeutic Targeten_US
dc.subjectNeuropathic Painen_US
dc.subjectActivationen_US
dc.subjectItchen_US
dc.subjectMiceen_US
dc.subjectResponsesen_US
dc.subjectModelen_US
dc.subjectAntinociceptionen_US
dc.titleInvolvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonisten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu